# A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults

> **NCT06494527** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.** · enrollment: 30 (estimated)

## Conditions studied

- Safety Issues

## Interventions

- **DRUG:** RG002C0106

## Key facts

- **NCT ID:** NCT06494527
- **Lead sponsor:** Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-18
- **Primary completion:** 2026-08-20
- **Final completion:** 2026-08-20
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06494527

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06494527, "A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT06494527. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*